Synpromics expands facilities to meet demand for revolutionary gene control technology

“Our move to Roslin is the result of two incredibly successful years for the company. In 2017 alone, we’ve signed gene therapy deals with a large, orphan disease pharma company and most recently with a US biotech specialising in gene editing and developing rare disease gene therapies. We’ve also signed bioprocessing deals with a top-10 pharma company and a global CDMO. Currently, the company has over ten active commercial gene therapy programmes and five bioprocessing programmes underway."

"Over that time Synpromics’ team has grown by over 100% and is one of our greatest assets. We look forward to working in our new high tech facilities as we continue to build the company for the future.” 

“The company’s recent successes have been greatly accelerated by our revolutionary PromPT™ technology." 

"PromPT™ is our unique bioinformatics engine, the culmination of over 10 years’ work, to enable data-driven synthetic promoter design. It has been hugely important in helping us build an extensive IP portfolio, for both our partners and ourselves, and is of substantial commercial value. We are particularly pleased with the suite of tightly regulated inducible promoters that we have created using our platform, and the excitement they generated at The Bioprocessing Summit in Boston this year”.

“We’re delighted to welcome Dr Alan Lamont to Synpromics as a non-executive director. Alan has extensive experience that will be extremely valuable to us as we grow. He’s held senior corporate and business development roles with leading UK and US companies including Acambis, AstraZeneca, Eli Lilly and Mundipharma International”. 

“Synpromics, as one of the UK’s most innovative companies working in gene medicine, is an ideal fit for our profile. Synpromics’ innovation has been attracting attention within the life sciences community and we look forward to providing an environment conducive for the business to realise its long-term growth ambition.”